Rapt Therapeutics (RAPT) News Today $30.14 +1.04 (+3.57%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$29.49 -0.65 (-2.14%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Rapt Therapeutics (NASDAQ:RAPT) Receives Average Rating of "Moderate Buy" from AnalystsOctober 6 at 2:39 AM | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 6 at 2:37 AM | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Sets New 12-Month High - Time to Buy?October 3 at 8:13 PM | marketbeat.comClear Street Maintains RAPT Therapeutics (RAPT) Buy RecommendationOctober 1, 2025 | msn.comRAPT Therapeutics stock rises after FDA clears IND for food allergy trialSeptember 29, 2025 | za.investing.comRapt Therapeutics: FDA clears IND application for Phase 2b trial of RPT904September 29, 2025 | msn.comRAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food AllergySeptember 29, 2025 | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Upgraded to "Outperform" at Leerink PartnersSeptember 28, 2025 | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Leerink PartnrsSeptember 27, 2025 | marketbeat.comRapt Therapeutics $RAPT Shares Sold by Goldman Sachs Group Inc.September 27, 2025 | marketbeat.comRAPT Therapeutics stock rises after Leerink upgrades on food allergy opportunitySeptember 26, 2025 | za.investing.comLeerink upgrades Rapt Therapeutics on food allergy opportunity for RPT904September 26, 2025 | msn.comLeerink Partners Upgrades RAPT Therapeutics (RAPT)September 26, 2025 | msn.comRapt Therapeutics (NASDAQ:RAPT) Raised to Outperform at Leerink PartnersSeptember 26, 2025 | marketbeat.comLB Pharmaceuticals appoints William Kane, Rekha Hemrajani to boardSeptember 25, 2025 | msn.comRapt Therapeutics $RAPT Position Decreased by AJU IB Investment Co. Ltd.September 19, 2025 | marketbeat.comRapt Therapeutics $RAPT Shares Sold by Medicxi Ventures Management Jersey LtdSeptember 16, 2025 | marketbeat.comRapt Therapeutics $RAPT Shares Bought by Comerica BankSeptember 15, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street ZenSeptember 15, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 13, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street ZenSeptember 8, 2025 | marketbeat.comRAPT Therapeutics to Participate in Multiple Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 18, 2025 | marketbeat.comRapt Therapeutics price target raised to $9 from $8 at UBSAugust 12, 2025 | msn.comHC Wainwright Issues Positive Forecast for RAPT EarningsAugust 11, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street ZenAugust 10, 2025 | marketbeat.comRAPT Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comRapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" RatingJuly 31, 2025 | marketbeat.comRAPT Therapeutics Unveils Plans for RPT904 DevelopmentJuly 30, 2025 | theglobeandmail.comRapt Therapeutics upgraded to Neutral from Underweight at JPMorganJuly 30, 2025 | msn.comJP Morgan Upgrades RAPT Therapeutics (RAPT)July 30, 2025 | msn.comRapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street ZenJuly 26, 2025 | marketbeat.comQ2 Earnings Forecast for RAPT Issued By Lifesci CapitalJuly 25, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform RecommendationJuly 23, 2025 | msn.comRapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci CapitalJuly 23, 2025 | marketbeat.comRapt Therapeutics initiated with an Outperform at LifeSci CapitalJuly 23, 2025 | msn.comRapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from AnalystsJuly 23, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15, 2025 | msn.comAegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the BoardJuly 15, 2025 | tmcnet.comHC Wainwright Analysts Decrease Earnings Estimates for RAPTJuly 14, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) StockJuly 10, 2025 | marketbeat.comRAPT Therapeutics Inc.July 5, 2025 | barrons.comRAPT Therapeutics Inc Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMRapt Therapeutics (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsJune 28, 2025 | marketbeat.comRAPT Therapeutics expands board with two new directorsJune 25, 2025 | investing.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors - NasdaqJune 25, 2025 | nasdaq.comRAPT Therapeutics Names Two Industry Veterans to its Board of DirectorsJune 23, 2025 | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Lowered to Sell Rating by Wall Street ZenJune 21, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?June 18, 2025 | marketbeat.com Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPT Media Mentions By Week RAPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.120.54▲Average Medical News Sentiment RAPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼72▲RAPT Articles Average Week Get the Latest News and Ratings for RAPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Rapt Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Harrow News Today Aurinia Pharmaceuticals News Today Immunocore News Today Edgewise Therapeutics News Today Twist Bioscience News Today Cogent Biosciences News Today Biohaven News Today Harmony Biosciences News Today Phibro Animal Health News Today Vericel News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
